AnaptysBio Phase 2a data breakdown and Biotech portfolio reveal!

-AnaptysBio shows positive phase 2a data from their peanut allergy study with ANB020 https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-announces-positive-top-line-proof-concept-data-anb020 -Check out the PRACTALL guidelines for Oral Food Challenges https://www.siaip.it/upload/Standardizing_DBPCFC_PRACTALL_2012.pdf -I’m not taking a position because with such a small sample size, and convoluted inclusion criteria, I need to see more data

Going Nuts for Oral Immunotherapy – AIMT

Peanut allergy is reported to affect ~3 million Americans and there are approximately 210,000 emergency department visits attributed to food anaphylaxis in the USA per year (Sicherer SH, 2010, Clark S, 2013). Given that the only treatment for accidental ingestion of allergens is intramuscular epinephrine, companies have sought other ways to help patients with peanut […]